Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 10/20 | 0.45 |
| ▸ | DRD3 | P35462 | 10/20 | 0.45 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.44 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.43 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.41 |
| ▸ | CASP1 | P29466 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | MGLL | Q99685 | 1/20 | 0.40 |
| ▸ | GRM5 | P41594 | 1/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.39 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1764996 | 1.00 | DRD2 (0.45) | DRD2DRD3HRH3USP30GRIN2B | |
| SCHEMBL1764638 | 0.82 | OPRM1 (0.54) | OPRM1OPRD1 | |
| SCHEMBL1764639 | 0.82 | OPRM1 (0.54) | OPRM1OPRD1 | |
| SCHEMBL1424660 | 0.81 | CHRM2 (0.48) | DRD2DRD3HRH3CYP2D6TSHR | |
| SCHEMBL1424659 | 0.81 | CHRM2 (0.48) | DRD2DRD3HRH3CYP2D6TSHR | |
| SCHEMBL10295474 | 0.77 | DRD3 (0.58) | DRD2DRD3CYP2D6TSHRNFKB1 | |
| SCHEMBL12314095 | 0.77 | DRD3 (0.58) | DRD2DRD3CYP2D6TSHRNFKB1 | |
| SCHEMBL25652855 | 0.77 | DRD2 (0.52) | DRD2DRD3HRH3USP30GRIN2B | |
| SCHEMBL1773689 | 0.75 | DRD2 (0.51) | DRD2DRD3OPRM1OPRD1 | |
| SCHEMBL1773690 | 0.75 | DRD2 (0.51) | DRD2DRD3OPRM1OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230183232-A1 | 8-AZABICYCLO[3.2.1]OCTANE COMPOUNDS AS MU OPIOID RECEPTOR ANTAGONISTS | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2023-06-15 | — | — | US | disclosed |
| US-11548887-B2 | 8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2023-01-10 | — | — | US | disclosed |
| US-20210024515-A1 | 8-AZABICYCLO[3.2.1]OCTANE COMPOUNDS AS MU OPIOID RECEPTOR ANTAGONISTS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2021-01-28 | — | — | US | disclosed |
| US-10745394-B2 | 8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2020-08-18 | — | — | US | disclosed |
| US-20190308966-A1 | 8-AZABICYCLO[3.2.1]OCTANE COMPOUNDS AS MU OPIOID RECEPTOR ANTAGONISTS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2019-10-10 | — | — | US | disclosed |
| US-10426766-B2 | Crystalline forms of an 8-azabicyclo[3.2.1]octane compound | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2019-10-01 | — | — | US | disclosed |
| US-10377751-B2 | 8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2019-08-13 | — | — | US | disclosed |
| US-20190119267-A1 | 8-AZABICYCLO[3.2.1]OCTANE COMPOUNDS AS MU OPIOID RECEPTOR ANTAGONISTS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2019-04-25 | — | — | US | disclosed |
| US-10081626-B2 | 8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2018-09-25 | — | — | US | disclosed |
| US-20180200246-A1 | CRYSTALLINE FORMS OF AN 8-AZABICYCLO[3.2.1]OCTANE COMPOUND | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2018-07-19 | — | — | US | disclosed |
| US-7943772-B2 | Crystalline forms of an 8-azabicyclo(3.2.1)octane compound | THERAVANCE, INC. (US) | 2011-05-17 | — | — | US | disclosed |
| US-7902221-B2 | Amidoalkyl-8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists | THERAVANCE, INC. (US) | 2011-03-08 | — | — | US | disclosed |
| US-20100152199-A1 | HETEROARYLALKYL-8-AZABICYCLO[3.2.1]OCTANE COMPOUNDS AS MU OPIOID RECEPTOR ANTAGONISTS | THERAVANCE, INC. (US) | 2010-06-17 | — | — | US | disclosed |
| US-7691878-B2 | Heteroarylalkyl-8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists | THERAVANCE, INC. (US) | 2010-04-06 | — | — | US | disclosed |
| US-20100035921-A1 | 8-AZABICYCLO[3.2.1]OCTANE COMPOUNDS AS MU OPIOID RECEPTOR ANTAGONISTS | THERAVANCE, INC. (US) | 2010-02-11 | — | — | US | disclosed |
| US-7622508-B2 | 3-Endo-(8-{2-[cyclohexylmethyl-(2-hydroxyacetyl)-amino]-ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-benzamide; for treating condition associated with mu opioid receptor activity, e.g. a disorder of reduced motility of gastrointestinal tract such as opioid-induced bowel dysfunction and post-operative ileus | THERAVANCE, INC. (US) | 2009-11-24 | — | — | US | disclosed |
| US-20090062335-A1 | Amidoalkyl-8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists | THERAVANCE, INC. | 2009-03-05 | — | — | US | disclosed |
| US-20090062334-A1 | Heteroarylalkyl-8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists | THERAVANCE, INC. | 2009-03-05 | — | — | US | disclosed |
| US-20080207676-A1 | Crystalline forms of an 8-Azabicyclo(3.2.1)octane compound | THERAVANCE BIOPHARMA R&D IP, LLC | 2008-08-28 | — | — | US | disclosed |
| US-20070219278-A1 | 3-Endo-(8-{2-[cyclohexylmethyl-(2-hydroxyacetyl)-amino]-ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-benzamide; for treating condition associated with mu opioid receptor activity, e.g. a disorder of reduced motility of gastrointestinal tract such as opioid-induced bowel dysfunction and post-operative ileus | THERAVANCE BIOPHARMA R&D IP, LLC | 2007-09-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (16 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190308966-A1 | 8-AZABICYCLO[3.2.1]OCTANE COMPOUNDS AS MU OPIOID RECEPTOR ANTAGONISTS | OPRM1, OPRD1, OPRK1 | DRD2 121/4885DRD3 108/4885HRH3 684/4885 |
| US-20210024515-A1 | 8-AZABICYCLO[3.2.1]OCTANE COMPOUNDS AS MU OPIOID RECEPTOR ANTAGONISTS | OPRM1, OPRD1, OPRK1 | DRD2 121/4885DRD3 108/4885HRH3 684/4885 |
| US-10377751-B2 | 8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists | OPRM1, OPRD1, OPRK1 | DRD2 121/4885DRD3 108/4885HRH3 684/4885 |
| US-20190119267-A1 | 8-AZABICYCLO[3.2.1]OCTANE COMPOUNDS AS MU OPIOID RECEPTOR ANTAGONISTS | OPRM1, OPRD1, OPRK1 | DRD2 121/4885DRD3 108/4885HRH3 684/4885 |
| US-20180200246-A1 | CRYSTALLINE FORMS OF AN 8-AZABICYCLO[3.2.1]OCTANE COMPOUND | OPRM1, SIGMAR1, OPRD1 | DRD2 587/4885DRD3 342/4885HRH3 1528/4885 |
| US-10426766-B2 | Crystalline forms of an 8-azabicyclo[3.2.1]octane compound | OPRM1, SIGMAR1, OPRD1 | DRD2 587/4885DRD3 342/4885HRH3 1528/4885 |
| US-10745394-B2 | 8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists | OPRM1, OPRD1, OPRK1 | DRD2 121/4885DRD3 108/4885HRH3 684/4885 |
| US-20230183232-A1 | 8-AZABICYCLO[3.2.1]OCTANE COMPOUNDS AS MU OPIOID RECEPTOR ANTAGONISTS | OPRM1, OPRD1, OPRK1 | DRD2 121/4885DRD3 108/4885HRH3 684/4885 |
| US-20080207676-A1 | Crystalline forms of an 8-Azabicyclo(3.2.1)octane compound | OPRM1, SIGMAR1, OPRD1 | DRD2 597/4885DRD3 354/4885HRH3 1476/4885 |
| US-10081626-B2 | 8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists | OPRM1, OPRD1, OPRK1 | DRD2 121/4885DRD3 108/4885HRH3 684/4885 |
| US-20100152199-A1 | HETEROARYLALKYL-8-AZABICYCLO[3.2.1]OCTANE COMPOUNDS AS MU OPIOID RECEPTOR ANTAGONISTS | OPRM1, OPRD1, OPRK1 | DRD2 117/4885DRD3 168/4885HRH3 462/4885 |
| US-20090062335-A1 | Amidoalkyl-8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists | OPRM1, OPRL1, OPRK1 | DRD2 154/4885DRD3 195/4885HRH3 464/4885 |
| US-20100035921-A1 | 8-AZABICYCLO[3.2.1]OCTANE COMPOUNDS AS MU OPIOID RECEPTOR ANTAGONISTS | OPRM1, OPRD1, OPRK1 | DRD2 121/4885DRD3 108/4885HRH3 684/4885 |
| US-11548887-B2 | 8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists | OPRM1, OPRD1, OPRK1 | DRD2 121/4885DRD3 108/4885HRH3 684/4885 |
| US-20090062334-A1 | Heteroarylalkyl-8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists | OPRM1, OPRD1, OPRK1 | DRD2 117/4885DRD3 168/4885HRH3 462/4885 |
| US-20070219278-A1 | 3-Endo-(8-{2-[cyclohexylmethyl-(2-hydroxyacetyl)-amino]-ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-benzamide; for treating condition associated with mu opioid receptor activity, e.g. a disorder of reduced motility of gastrointestinal tract such as opioid-induced bowel dysfunction and post-operative ileus | OPRM1, OPRD1, OGFR | DRD2 315/4885DRD3 317/4885HRH3 166/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.